Jana Hummel

Jana Hummel


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2011 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
JHJana Hummel
Jana Hummel
SWSabine Westphal
Sabine Westphal
BWBettina Weber-Hamann
Bettina Weber-Hamann
MGMaria Gilles
Maria Gilles
FLFlorian Lederbogen
Florian Lederbogen
DKDaniel Kopf
Daniel Kopf
Despite reports of lower plasma cholesterol in depressed patients, major depressive disorder has been shown to increase cardiovascular risk. Our objective was to study the composition of lipoproteins in depressed patients and controls and to examine the effects of pharmacologic treatment and treatment response on lipoprotein composition. Lipoprotein composition was analyzed in 65 adult inpatients at a university psychiatric hospital in Germany with DSM-IV major depressive disorder and 33 healthy controls (recruited via newspaper and radio ads) matched for age and sex. After the cross-sectional study phase, the patients were randomized in an open-label prospective trial to treatment with either mirtazapine or venlafaxine. Lipoproteins were reanalyzed after 4 weeks of treatment. Main outcome measures were total cholesterol, the low-density lipoprotein (LDL) to high-density lipoprotein (HDL) cholesterol ratio, and the LDL triglycerides to apolipoprotein B ratio. Secondary outcome measures were total triglycerides, HDL and LDL cholesterol levels, and apolipoproteins A1 and B levels. Comparisons were made between the 2 drug groups and between remitters and nonremitters as measured by the 21-item Hamilton Depression Rating Scale. The study was conducted from April 2003 through December 2007. Total cholesterol at baseline was lower in patients than in controls (mean ± SD = 4.99 ± 0.98 mmol/L vs 5.63 ± 1.01 mmol/L; P = .003), with significantly lower HDL cholesterol (P < .001) and LDL cholesterol (P = .03) in patients. However, the ratio of LDL triglycerides to apolipoprotein B, an index of size and atherogenic potential of LDL particles, was higher in depressed subjects (mean ± SD = 0.46 ± 0.14 mmol/g vs 0.38 ± 0.09 mmol/g; P = .002). Irrespective of treatment allocation, we found significant improvement of cardiovascular risk parameters in remitters but found deterioration in nonresponders. The LDL cholesterol mean change from baseline (remitters vs partial responders vs nonresponders) was -0.06 mmol/L versus +0.39 mmol/L versus +0.56 mmol/L (P = .014); the mean change in LDL/HDL cholesterol ratio was -0.50 versus +0.14 versus +0.80 (P = .002); and the mean change in the LDL triglycerides per apolipoprotein B ratio was -0.01 versus -0.01 versus +0.08 (P = .045). No drug-specific changes in lipid concentrations during treatment were observed except for total cholesterol (venlafaxine group mean = -0.02 mmol/L and mirtazapine group mean = +0.37 mmol/L; P = .033). In depressed patients, lipoprotein structure is changed toward LDL particles with a higher atherogenic potential. Remission from depression is associated with an improvement of the LDL/HDL cholesterol ratio, shifting lipoproteins toward a less atherogenic composition. Our findings should be confirmed in a larger study, as they have relevance for both researchers and clinicians. German Clinical Trial Registry Identifier: DRKS00000008.

1 March 2014 in Patient Education and Counseling
Verified
Journal Article
Closed access
ABAnke Bahrmann
Anke Bahrmann
AAAmelie Abel
Amelie Abel
AZAndrej Zeyfang
Andrej Zeyfang
FPFrank Petrak
Frank Petrak
TKThomas Kubiak
Thomas Kubiak
PBPhilipp Bahrmann
Philipp Bahrmann

6 April 2011 in Experimental and Clinical Endocrinology & Diabetes
Verified
Journal Article
Closed access
PDF file
FLF. Lederbogen
F. Lederbogen
JHJana Hummel
Jana Hummel
CFC. Fademrecht
C. Fademrecht
BKB. Krumm
B. Krumm
CKC. Kühner
C. Kühner
BBB. Breivogel
B. Breivogel
Introduction: While altered cortisol concentrations have been observed in subjects with type 2 diabetes their circadian cortisol profile is unknown. Patients and methods: Using a cross-sectional design, we studied 63 ambulatory individuals with type 2 diabetes and 916 non-diabetic control subjects of the Cooperative Research in the Region of Augsburg (KORA)-F3 study. Circadian cortisol profiles were derived from saliva cortisol concentrations, determined on a regular weekday upon wake-up (F0), as well as œ h (Fœ), 8 (F8) and 14 h (F14) after wake-up. Results: Diabetic subjects exhibited a flattened circadian cortisol profile (rm-ANOVA: F[3,654]=3.41, p=0.02), with lower morning and higher afternoon and evening cortisol concentrations. Conclusion: We observed a flattened circadian cortisol rhythm in subjects with type 2 diabetes, providing evidence for a specific HPA system dysfunction.

1 April 2017 in Journal of the American Medical Directors Association
Verified
Journal Article
Closed access
JHJana Hummel
Jana Hummel
CWCecilia Weisbrod
Cecilia Weisbrod
LBLeila Boesch
Leila Boesch
KHKatharina Himpler
Katharina Himpler
KHKlaus Hauer
Klaus Hauer
DKDaniel Kopf
Daniel Kopf

20 December 2012 in Zeitschrift für Gerontologie und Geriatrie
Verified
Journal Article
Closed access
PDF file
DKD. Kopf
D. Kopf
JHJana Hummel
Jana Hummel

27 January 2012 in Zeitschrift für Gerontologie und Geriatrie
Verified
Journal Article
Closed access
PDF file
JHJana Hummel
Jana Hummel
CWC. Weisbrod
C. Weisbrod
LBL. Bösch
L. Bösch
KHK. Himpler
K. Himpler
GBG. Böhm
G. Böhm
DKD. Kopf
D. Kopf